Modified Nucleotidyl Transferases for Enzymatically Mediated Oligodeoxynucleotide Synthesis

Information

  • Research Project
  • 8904404
  • ApplicationId
    8904404
  • Core Project Number
    R43HG008562
  • Full Project Number
    1R43HG008562-01
  • Serial Number
    008562
  • FOA Number
    PA-14-071
  • Sub Project Id
  • Project Start Date
    8/1/2015 - 9 years ago
  • Project End Date
    5/31/2016 - 8 years ago
  • Program Officer Name
    SMITH, MICHAEL
  • Budget Start Date
    8/1/2015 - 9 years ago
  • Budget End Date
    5/31/2016 - 8 years ago
  • Fiscal Year
    2015
  • Support Year
    01
  • Suffix
  • Award Notice Date
    7/17/2015 - 9 years ago

Modified Nucleotidyl Transferases for Enzymatically Mediated Oligodeoxynucleotide Synthesis

? DESCRIPTION (provided by applicant): In the rapidly growing field of synthetic biology the cost of synthetic DNA for gene synthesis has become a substantial part of many laboratory budgets. Current DNA synthesis technologies are unable to produce gene length DNA fragments and rely on expensive and error prone assembly methods to construct long strands of DNA. In addition, current DNA synthesis methods are organic chemistry based and produce toxic waste mixtures that are difficult and costly to dispose of. Here we propose to design a novel biologically based DNA synthesis method which will enable the high fidelity, template independent, synthesis of long (>500bp) strands of DNA. This proposal describes a novel method that will lead to reduced costs in every synthetic biology laboratory, enabling applications such as faster development of vaccines, biomolecular computation, reprograming of cells and improved cellular therapeutics. The resulting massively parallel synthesis capability developed in Phase II of this project will be put to use as a custom synthesis service by Molecular Assemblies similar to how custom oligos are ordered, produced and delivered today. To achieve this, this proposal focuses on engineering the enzyme terminal deoxynucleotidyl transferase (TdT), which acts by adding nucleotides to single stranded DNA in a template-independent fashion, to utilize modified deoxynucleotide triphosphates (dNTPs). The dNTP analogs are blocked in such a way that leads to the addition of one and only one nucleotide of choice at a time and, after being added to the growing strand, are able to be de-blocked to regenerate a natural DNA strand. Phase I covers the development of an engineered enzyme and its use to prove the ability to make a short sequence specific nucleic acid. Phase II will lead to optimization of all four dNTP analogs, cycle conditions, automation and the demonstration of the full capabilities of this novel, synthetic approach for polydeoxynucleotides. In 1981 it would have been difficult to envision the specific fundamental roles DNA synthesis would eventually play in modern biology; while the idea of purchasing synthetic genes was a concept of science fiction. One can only imagine how on-demand, high purity, low cost polynucleotides will enable a new era of biological & clinical applications.

IC Name
NATIONAL HUMAN GENOME RESEARCH INSTITUTE
  • Activity
    R43
  • Administering IC
    HG
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    189004
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    172
  • Ed Inst. Type
  • Funding ICs
    NHGRI:189004\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MOLECULAR ASSEMBLIES, INC.
  • Organization Department
  • Organization DUNS
    078770578
  • Organization City
    SAN CARLOS
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    940703761
  • Organization District
    UNITED STATES